Filing Flows

Filing Flows › Companies › Procept BioRobotics › Cash flow

Procept BioRobotics cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$9.7M in Q3 2026 · −$85.1M over twelve months

Operating cash flow−$9.0M
Capital spending−$667K
Free cash flow−$9.7M
Cash conversion cycle275 days

Analysis

In Q3 2026, Procept BioRobotics generated −$9.0M of operating cash flow and spent $667K on capital projects, leaving free cash flow of −$9.7M. That is $149K less than in Q3 2025 (−$9.5M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$76.7M; the largest uses were operating cash flow ($76.7M), capital spending ($8.4M); besides operations, cash came from other financing ($7.2M), shares issued ($2.1M); the cash balance fell by $75.9M.

Operating cash flow was −$9.0M against net income of −$26.5M. The largest differences: stock-based pay +$15.1M, inventory −$3.5M, other liabilities −$2.8M.

Its cash conversion cycle was 275 days (receivables 100 + inventory 220 − payables 44).

Free cash flow

Procept BioRobotics: free cash flow by quarterProcept BioRobotics: free cash flow by quarter−$33.6MQ4 2024−$18.8MQ1 2025−$17.8MQ2 2025−$9.5MQ3 2025−$12.2MQ4 2025−$41.0MQ1 2026−$22.2MQ2 2026−$9.7MQ3 2026
Operating cash flow less capital spending.
Procept BioRobotics: operating cash flow against capital spendingProcept BioRobotics: operating cash flow against capital spendingOperating cash flowCapital spending−$32.4M$1.2MQ4 2024−$17.0M$1.8MQ1 2025−$15.0M$2.8MQ2 2025−$6.6M$2.9MQ3 2025−$10.3M$1.9MQ4 2025−$38.1M$2.9MQ1 2026−$19.3M$3.0MQ2 2026−$9.0M$667KQ3 2026
Latest (Q3 2026): Operating cash flow −$9.0M, Capital spending $667K.

Capital allocation, year by year

Procept BioRobotics: where the cash came from (up) and went (down), by fiscal yearProcept BioRobotics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingFY2021: Operating cash flow −$57.3MFY2021: Shares issued $4.2MFY2021: Capital spending −$592K$4.2MFY2021FY2022: Operating cash flow −$80.4MFY2022: Shares issued $4.0MFY2022: Capital spending −$2.7M$4.0MFY2022FY2023: Operating cash flow −$108MFY2023: Shares issued $164MFY2023: Capital spending −$25.2M$164MFY2023FY2024: Operating cash flow −$99.2MFY2024: Shares issued $176MFY2024: Capital spending −$4.4M$176MFY2024FY2025: Operating cash flow −$49.0MFY2025: Shares issued $4.8MFY2025: Capital spending −$9.4M$4.8MFY2025
Over these 5 years operating cash flow totalled −$394M; the largest uses were operating cash flow ($394M) and capital spending ($42.2M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$218M
Debt$51.8M
Net cash$167M
Cash runway2.6 years

Procept BioRobotics is burning cash: its operations consume cash, a free cash flow of −$85.1M a year at the current rate against $218M of cash and investments: a runway of about 2.6 years before any new financing.

Procept BioRobotics: debt maturities by year (FY2024)Procept BioRobotics: debt maturities by year (FY2024)$8.7MYear 2$43.3MYear 3
Principal due in each year as disclosed in the annual report, against $218M of cash and investments now.

Where the cash came from and went

Procept BioRobotics: sources (+) and uses (−) of cash, Q3 2026Procept BioRobotics: sources (+) and uses (−) of cash, Q3 2026Cash drawn (+) / kept (−)$9.5MOperating cash flow−$9.0MCapital spending−$667KShares issued$99KExchange rates$8K
Procept BioRobotics: sources (+) and uses (−) of cash, TTM to Q3 2026Procept BioRobotics: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow−$76.7MCash drawn (+) / kept (−)$75.9MCapital spending−$8.4MOther financing$7.2MShares issued$2.1MExchange rates−$95K

From profit to cash

Procept BioRobotics: net income to operating cash flow, Q3 2026Procept BioRobotics: net income to operating cash flow, Q3 2026Net income−$26.5MDepreciation & amortization$2.5MStock-based pay$15.1MReceivables$2.0MInventory−$3.5MPayables$1.5MDeferred revenue$1.6MPrepaid and other assets−$1.7MOther liabilities−$2.8MOperating cash flow−$9.0M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 202610022044275
Q2 20269821948269
Q1 20269722956270
Q4 202510121043268
Q3 20259121036265
Q2 20259221544262
Q1 202510621345274
Q4 202410320047256

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$9.0M−$667K—$99K$9.5M−$9.7M
Q2 2026−$19.3M−$3.0M—$183K$17.7M−$22.2M
Q1 2026−$38.1M−$2.9M—$222K$40.9M−$41.0M
Q4 2025−$10.3M−$1.9M—$1.6M$7.8M−$12.2M
Q3 2025−$6.6M−$2.9M−$1K$1.1M$8.4M−$9.5M
Q2 2025−$15.0M−$2.8M—$873K$13.5M−$17.8M
Q1 2025−$17.0M−$1.8M—$1.3M$17.5M−$18.8M
Q4 2024−$32.4M−$1.2M−$2.1M$168M−$137M−$33.6M

Procept BioRobotics: income statement and cash flow

Procept BioRobotics, Q3 2026: revenue $98.3M (+18% year over year), operating margin -27.9%. The chart follows the revenue to costs, profit and cash.

Procept BioRobotics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.